Located in Lugano, Switzerland, Helsinn Holding, SA was established as a pharmaceutical and biotech company in 1976. The company operates to improve the quality of cancer care and medical products for rare diseases. In 2021, Helsinn Holding made a poster presentation at the Academy of Managed Care Pharmacy (AMCP) National Meeting.
The poster, entitled Avoiding Acute Care and Unplanned Hydrations from Chemotherapy-Induced Nausea and Vomiting (CINV) in Real World Practice, explores CINV, one of the leading causes of acute care events over the course of chemotherapy treatments. Research indicates about one in nine acute care events can be linked to CINV. By addressing CINV toxicity and minimizing otherwise avoidable instances of acute care, medical facilities can elevate cancer care services and reduce expenses.
In assembling the poster, Helsinn's team analyzed Medicare data from 17 oncology practices over three and a half years, focusing on CINV acute care following emetogenic chemotherapy. The AMCP National Meeting took place as a virtual event from April 12-16, 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.